IGF-DES side effects and safety context

Among the IGF-1 variants that have been compared head to head in animals, des(1-3)IGF-I was the most potent at lowering blood glucose. That is the central safety fact about this compound, and it follows directly from what makes it interesting: deleting the N-terminal tripeptide removes the glutamate at position 3, which is the residue responsible for IGF-binding-protein affinity. Less buffering means more free peptide acting on insulin-like pathways.

The common counterargument — that DES is short-acting, so the risk is self-limiting — does not survive contact with the primary data.

The comparison study administered IGF-I alongside four binding-resistant variants and insulin to pigs and marmoset monkeys, sampling blood from 30 minutes before to four hours after a bolus (PMID 9415072):

• Hypoglycemic potency ranked IGF-I < long-IGF-I < R3IGF-I ≈ LR3IGF-I < des(1-3)IGF-I — with DES at the top — and potency tracked the variants' reduced affinity for the binding proteins.
• The variants as a class were 2- to 3-fold more potent than IGF-I at driving glucose to its nadir, and produced roughly 4- to 8-fold greater cumulative hypoglycemia across four hours.
• Maximum glucose lowering reached 4.8 mmol/L in the pig, 3.7 in the conscious marmoset, and 2.5 in the anaesthetised marmoset — the pig being the more sensitive species.
• Marmoset doses ranged from 42 to 270 µg/kg; pig doses were 20 and 50 µg/kg for the IGFs against 3 µg/kg for insulin.

Symptoms of low blood glucose — shakiness, sweating, confusion, and in severe cases seizures or loss of consciousness — are the clinical expression of these numbers. Anything else lowering glucose concurrently (insulin, other glucose-lowering agents, fasting, prolonged exercise) adds to the same curve.

Less than the framing suggests. Two findings in the same study argue against treating brevity as a safety margin.

First, the prolonged glucose suppression seen with the binding-resistant variants was not simply proportional to the depth of the nadir: at doses equipotent for glucose lowering, the cumulative hypoglycemic effect of the variants was still about double that of IGF-I. Duration and depth came apart. Second, the authors could not account for the differential effect in the marmoset through changes in plasma insulin, IGF-I, or IGFBP levels, and postulated indirect effects via glucagon inhibition or direct action at hepatic insulin receptors — mechanisms that outlast the peptide's presence in plasma.

A molecule can clear quickly and still leave a metabolic effect running. The half-life describes the peptide, not the physiology it set in motion.

Mecasermin (Increlex), the FDA-approved full-length recombinant IGF-1, provides the only regulatory safety document for this class (Increlex label, DailyMed). Its warnings include severe hypoglycemia leading to hypoglycemic seizures — managed by requiring administration within ±20 minutes of a meal or snack and withholding the dose entirely if the patient cannot eat — plus hypersensitivity and anaphylaxis, intracranial hypertension monitored by funduscopic examination, tonsillar and adenoidal hypertrophy, and slipped capital femoral epiphysis. It is contraindicated in closed epiphyses and malignant neoplasia.

Those precautions attach to a molecule that still responds to binding proteins. DES ranked as the most potent variant precisely because it does not.

IGF-1 receptor activation is a proliferation and survival signal across many tissue types. Prospective data from 394,388 cancer-free UK Biobank participants found each 5 nmol/L higher serum IGF-I associated with modestly increased risk of colorectal (HR 1.08), breast (HR 1.11), prostate (HR 1.08), and thyroid cancer (HR 1.18), alongside reduced risks of ovarian and liver cancer (PMID 32709735).

Those associations describe endogenous IGF-I within its physiologic range over a mean 6.9 years of follow-up, and the authors note reverse causality cannot be excluded — so they do not transfer as a risk estimate for an exogenous analog. What they do establish is that the IGF-1 axis is not a neutral system to push on without data, and for DES there is no human data at all.

IGF-DES is sold as a research chemical with no verified identity, purity, sterility, or peptide content. Injection-site reactions and non-specific symptoms such as headache and fatigue are the mundane end of this; the consequential end is that a microgram-dosed compound whose defining hazard is hypoglycemia is being measured from a vial whose actual contents nobody has confirmed. The dosing page covers why that uncertainty multiplies rather than adds.